| Business Summary | | Advanced
Viral
Research
Corp.
engages
in
the
production
and
marketing,
promotion
and
sale
of
the
pharmaceutical
drug,
Reticulose,
for
the
treatment
of
certain
viral
and
autoimmune
diseases
such
as
human
immunodeficiency
virus
(HIV),
including
acquired
immune
deficiency
syndrome
(AIDS);
hepatitis
B
and
hepatitis
C
liver
diseases;
human
papilloma
virus
(HPV),
which
causes
genital
warts
and
may
lead
to
cervical
cancer,
and
rheumatoid
arthritis.
The
Company's
operations
have
been
limited
principally
to
research,
testing
and
analysis
of
Reticulose
in
the
United
States,
either
in
vitro
(outside
the
living
body
in
an
artificial
environment,
such
as
in
a
test
tube)
or
on
animals,
and
engaging
others
to
perform
testing
and
analysis
of
Reticulose
on
human
patients
outside
the
United
States.
The
Food
and
Drug
Administration
has
not
approved
human
clinical
trials
for
Reticulose
in
the
United
States. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ADVR
is
engaged
in
the
production
and
marketing,
promotion
and
sale
of
a
pharmaceutical
drug
with
the
trade
name
Reticulose.
Reticulose
has
not
yet
been
approved
for
sale
or
use
by
the
FDA
in
any
foreign
government
body.
For
the
six
months
ended
6/30/01,
net
sales
totalled
$11
thousand,
up
from
$5
thousand.
Net
loss
rose
46%
to
$4.9
million.
Revenues
reflect
an
increase
in
distributor
purchases
of
Reticulose.
Higher
loss
reflects
increased
R&D
expenses
related
to
GloboMax. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Bernard Friedland, 75 Chairman | -- | Shalom Hirschman, M.D., 64 Pres,
CEO, Director and Chief Scientific Officer | $396K | Alan Gallantar, 43 CFO | 246K | William Bregman, 79 VP,
Sec., Treasurer, Director | -- | Raymond Tudor VP,
Drug Devel. | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|